Mersana receives Nasdaq deficiency notice for MVLS below $50M

Mersana Therapeutics, Inc.

Notice received September 5, 2025; MRSN must regain compliance by March 4, 2026.
Company's MVLS must close at $50M or more for 10 consecutive business days.
If not compliant by deadline, Nasdaq will issue delisting notice; company can appeal.
Stock continues trading on Nasdaq Global Select Market under symbol MRSN.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.